Clade Therapeutics

Gadeta is a research and development company focused on creating innovative immunotherapies for cancer treatment. It has developed a technology platform that utilizes combinatorial T cell receptor exchange to produce optimized gamma delta T-cell receptors with enhanced anti-cancer properties. Gadeta’s primary product, T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs), shows significant therapeutic potential for targeting and eliminating both hematological and solid tumors. The company's approach leverages high-affinity gamma delta TCRs expressed on alpha beta T cells, which possess superior proliferation capacity, aiming to improve outcomes for patients with advanced malignancies. Through its research, Gadeta seeks to contribute to the eradication of cancer and enhance treatment efficacy across various types of tumors.